Determining When to Add Nonstatin Therapy: A Quantitative Approach

Lipid-Lowering Drugs

A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention

JAMA Cardiol.

Thanassoulis G, Sniderman AD, Pencina MJ

doi: 10.1001/jamacardio.

Myocardial Infarction

Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials

Clin Res Cardiol.

Stienen S, Rossignol P, Barros A, Girerd N, Pitt B, Zannad F, Ferreira JP

doi: 10.1007/s00392-019-01500-3.

Hypertension

New insights in diagnostics and therapies in syncope: a novel approach to non-cardiac syncope

Heart

Brignole M, Rivasi G

doi: 10.1136/heartjnl-2020-318261

Myocardial InfarctionThrombosis and StrokeTherapy and Intervention

Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial

J Am Coll Cardiol.

Notarangelo FM, Maglietta G, Bevilacqua P, Cereda M, Merlini PA, Villani GQ, Moruzzi P, Patrizi G, Malagoli Tagliazucchi G, Crocamo A, Guidorossi A, Pigazzani F, Nicosia E, Paoli G, Bianchessi M, Comelli MA, Caminiti C, Ardissino D

doi: 10.1016/j.jacc.2018.02.029.

Thrombosis and Stroke

Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting

Lancet.

Breitenstein C, Grewe T, Flöel A, Ziegler W, Springer L, Martus P, Huber W, Willmes K, Ringelstein EB, Haeusler KG, Abel S, Glindemann R, Domahs F, Regenbrecht F, Schlenck KJ, Thomas M, Obrig H, de Langen E, Rocker R, Wigbers F, Rühmkorf C, Hempen I, List J, Baumgaertner A; FCET2EC study group.

doi: 10.1016/S0140-

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

JAMA Cardiol.

Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ

doi: 10.1001/

Atrial Fibrillation

Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials

Eur Heart J.

Henry TD, Losordo DW, Traverse JH, Schatz RA, Jolicoeur EM, Schaer GL, Clare R, Chiswell K, White CJ, Fortuin FD, Kereiakes DJ, Zeiher AM, Sherman W, Hunt AS, Povsic TJ

doi: 10.1093/eurheartj/ehx764.

Atrial Fibrillation

Improving Atrial Fibrillation Therapy: Is There a Gene for That?

J Am Coll Cardiol.

Hucker WJ, Hanley A, Ellinor PT

doi: 10.1016/j.jacc.2017.02.043.

Heart, Artery and Coronary DiseasesThrombosis and StrokeTherapy and Intervention

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)